Congress of Clinical Rheumatology (CCR) East, 2024 

Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies

Rapid, Sustained Improvements in Routine Assessment of Patient Index Data 3 in Bimekizumab-Treated Patients With Psoriatic Arthritis: Post-Hoc Analysis of Two Phase 3 Studies

Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-αα Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study

Bimekizumab Safety in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Rates of Hepatic Events and Transaminase Elevations in Phase 3 Trials

Reporting mental health and associated disorders from trials of bimekizumab in patients with active axial spondyloarthritis and psoriatic arthritis